Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Calcipotriene/betamethasone Clear all
Completed Phase 2 Interventional Results available

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

NCT00820950
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 26, 2026, 1:47 AM EDT
Completed No phase listed Observational

An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

NCT01982552
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Not listed
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Phoenix, Arizona • Fremont, California • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Results available

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

NCT01745133
View directory record Official record
Conditions
Psoriasis
Interventions
vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
Drug
Lead sponsor
Leon Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 26, 2026, 1:47 AM EDT
Recruiting Phase 4 Interventional

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

NCT03827876
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%, SOR007 Ointment 0.15%, SOR007 Ointment Placebo, Taclonex® Ointment
Drug
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

NCT03892564
View directory record Official record
Conditions
Phototoxicity
Interventions
MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

NCT01866163
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 26, 2026, 1:47 AM EDT
Recruiting Phase 4 Interventional

Taltz in Combination With Enstilar for Psoriasis

NCT04372277
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

NCT01188928
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene, Topical suspension vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

NCT03462927
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 Cream, CAL/BDP combination
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Sweetwater, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 4 Interventional

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar, Deucravacitinib
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 26, 2026, 1:47 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

NCT00608777
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Calcipotriene/betamethasone
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

NCT03122353
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene and betamethasone suspension, Taclonex, Placebo
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

LEO 90100 in the Treatment of Psoriasis Vulgaris

NCT01536938
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Calcipotriol, Betamethasone
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

NCT02038569
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 80185 gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • Tampa, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

NCT01536886
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
39
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis

NCT04227288
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Enstilar Foam
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 4 Interventional

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

NCT00437255
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Fridley, Minnesota • Austin, Texas • Bryan, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene/betamethasone gel and ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 26, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug · Other
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
30
States / cities
Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 26, 2026, 1:47 AM EDT